Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

295

207 Comparative Effectiveness of Dupilumab Versus Omalizumab in Asthma Among Biologic-Naïve Patients: Findings From the Real-World US Advantage Study/ E.R. Bleecker, Tucson, AZ 208 Comparative Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients With Asthma/ C. Kearney, Boston, MA 209 Dupilumab Improves Lung Function in Children With Moderate-to-Severe Type 2 Asthma at Week 12/ T.W. Guilbert, Cincinnati, OH 210 Real-world Effectiveness of Dupilumab on Oral Corticosteroid Use and Asthma Exacerbations in Patients With Moderate-to-Severe Asthma/ A. Pawar, Cambridge, MA 211 Mepolizumab Provides Real-World Clinical Benefits in Severe Eosinophilic Asthma Irrespective of Baseline Lung Function: Results From the REALITI-A Study at 2 Years/ D. Bagnasco, Genoa, Italy 212 Exacerbation Burden and Biologic Outcomes in Us Patients With Severe Asthma by Obesity: Results From the Chronicle Study/ R. Panettieri, New Brunswick, NJ 213 Dupilumab Induces Clinical Remission in Patients With Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma/ I.D. Pavord, Oxford, United Kingdom 214 Efficacy of Tezepelumab in Patients Grouped by Pre-treatment Percent Predicted FEV 1 : A Pooled Analysis of the PATHWAY and NAVIGATOR Studies/ M.E. Wechsler, Denver, CO 215 Biologic Outcomes in US Hispanic and Black Patients With Severe Asthma: Results From the CHRONICLE Study/ J. Trevor, Birmingham, AL

801 Potential Impact of the European Union F-gas Regulation on Patients With Asthma and Chronic Lower Respiratory Diseases/ J.P. Bell, Baar, Switzerland 802 Use of Spirometry and Biomarker Profiling in Severe Asthma: There Is Room for Improvement/ H. Ortega, San Diego, CA 803 Addressing Uncontrolled Asthma Across Disease Severities Through Implementation of the Asthma Impairment and Risk Questionnaire (AIRQ ® ) and the Asthma Checklist/ D.A. Beuther, Denver, CO 804 Rates of Asthma Exacerbations Among Severe, Persistent Asthma Patients in the US Following Event Indicating Uncontrolled Disease/ A.F. Burnette, Washington, DC 805 Disparities in Adult Asthma Outcomes Among Disaggregated Asian Americans in the National Health Interview Survey/ A. Zhang, Stanford, CA 806 Enhancing Adoption of New Targeted Agents and Empowering Patients With Severe Asthma: The Role of Tethered Education for Health Care Providers and Patients/ C. Drexel, Needham, MA 807 Rate of Biologic Initiation in Patients With Severe Uncontrolled Asthma (SUA)/ T.C. Corbridge, Research Triangle Park, NC 808 Beginning to Address an Implementation Gap in Asthma: Providers’ Views of Reliever Usage of ICS-formoterol Inhalers in the United States/ J.G. Krings, Saint Louis, MO 809 Clinical Practices and Barriers to the Use of Single Maintenance and Reliever Therapy for Asthma/ S.E. Zaeh, New Haven, CT 810 Association of Anxiety and Depression With Adherence to Inhaler in Patients With Asthma/ A.A. Alqarni, Jeddah, Saudi Arabia 811 Inspiring Health Advances in Lung Care (INHALE): An Opportunity to Address Pediatric Asthma Health Disparities in Michigan/ T.C. Lewis, Ann Arbor, MI 812 Barriers and Facilitators to Stock Inhalers for Schools Programming in Illinois: Results From a Qualitative Data Analysis/ A.A. Pappalardo, Chicago, IL 813 Factors Associated With Asthma Biologic Prescribing and Adherence Among Adults in a Major Multi-hospital Health System/ P. Gleeson, Philadelphia, PA 814 Characterizing Inpatients With Asthma in the Intensive Care Unit From 2010-2018/ S. Chokkara, Chicago, IL 815 Real-world Impact of Switching to Mepolizumab From Other Biologics in Patients With Asthma/ A. Deb, Collegeville, PA

BEHAVIORAL • CLINICAL POSTER DISCUSSION SESSION

C102 ASTHMA AND COPD: ADVANCING

BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 209 A-C (Level 2)

Poster Viewing

2:15-3:00 3:00-4:15

Discussion

Chairing: V.G. Press, MD, MPH, ATSF, Chicago, IL

A.S. Gershon, MD, MSc, ATSF, Toronto, Canada L.J. Spece, MD, MS, Seattle, WA

ATS 2023 • Washington, DC